We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
<sup>68</sup>Ga-DOTA<sup>0</sup>-Tyr<sup>3</sup>-octreotide positron emission tomography in head and neck squamous cell carcinoma.
- Authors
Schartinger, Volker H.; Dudás, József; Decristoforo, Clemens; Url, Christoph; Schnabl, Johannes; Göbel, Georg; Virgolini, Irene J.; Riechelmann, Herbert; Rasse, Michael; Waitz, Dietmar; Putzer, Daniel
- Abstract
Purpose: 68Ga-labelled DOTA 0-Tyr 3-octreotide positron emission tomography (PET)/CT ( 68Ga-DOTATOC PET/CT) is a routinely used imaging modality for neuroendocrine tumours expressing somatostatin receptors (SSTRs). Recent studies have shown that SSTRs are also expressed in head and neck squamous cell carcinoma (HNSCC). This is the first prospective clinical trial investigating SSTR expression in patients with HNSCC using 68Ga-DOTATOC. Methods: Patients with previously untreated HNSCC underwent 68Ga-DOTATOC PET/CT (120 MBq, range 81–150 MBq). Tumour tracer uptake was scored, the maximum standardized uptake value (SUV max) was measured and the tumour to background uptake ratio was calculated. For each patient, PET/CT findings were correlated with immunohistochemical SSTR expression in tumour specimens. Results: Fifteen HNSCC patients were included in the study from May 2011 to May 2012. Tumour-specific 68Ga-DOTATOC uptake was detected in all patients with an median SUV max of 4.0 (range 2.2–6.5). Uptake was weak in seven (47 %), moderate in five (33 %) and strong in three (20 %) patients. All tumour specimens were SSTR positive on immunohistochemistry. Of the 15 patients, 14 were positive for SSTR subtype 2, characterized by the highest affinity to octreotide. Conclusion: SSTR expression in HNSCC can be visualized clinically using 68Ga-DOTATOC PET/CT. SSTR expression in HNSCC could provide a potential target for SSTR-based therapy in patients not amenable to standard treatment modalities, but this cannot be predicted by SSTR immunohistochemistry.
- Subjects
POSITRON emission tomography; NEUROENDOCRINE tumors; SOMATOSTATIN receptors; SQUAMOUS cell carcinoma; CLINICAL trials; IMMUNOHISTOCHEMISTRY
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2013, Vol 40, Issue 9, p1365
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-013-2442-7